| Paul S Holota, MD | |
|
4092 Foxwood Dr, Suite 101, Virginia Beach, VA 23462-5225 | |
| (757) 467-4200 | |
| Not Available |
| Full Name | Paul S Holota |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 25 Years |
| Location | 4092 Foxwood Dr, Virginia Beach, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457380685 | NPI | - | NPPES |
| 5879426 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 0101232560 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sentara Virginia Beach General Hospital | Virginia beach, VA | Hospital |
| Sentara Princess Anne Hospital | Virginia beach, VA | Hospital |
| Sentara Leigh Hospital | Norfolk, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Physicians Of Tidewater | 5092618462 | 150 |
News Archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of New Jersey denied Teva's motion to overturn an April 23, 2010, jury verdict finding the patent in suit not invalid. The Court also denied Wyeth and Nycomed's request for FDA to reset the date of Teva's final approval to January 2011, based on the fact that Teva has patent defenses remaining at the District Court, including patent misuse.
Codexis, Inc., a developer of industrial enzymes to enable the cost advantaged production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the FDA has approved a new process co-developed by Codexis for the manufacture of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia.
People with certain blood types are more likely to have blood clots or bleeding conditions, kidney stones, or pregnancy-induced hypertension, suggests a study published today in eLife.
One of the most significant ways in which the human brain is unique is the size and structure of the cerebral cortex. But what drives the growth of the human cortex, likely the foundation for our unique intellectual abilities?
Cell Therapeutics, Inc. announced the publication of results posted in the online journal of Cancer of a Phase I-II study that evaluated the safety and efficacy of pixantrone when used in combination with fludarabine, dexamethasone and rituximab replacing mitoxantrone in the standard FND-R regimen with FPD-R among 28 patients with relapsed or refractory indolent non-Hodgkin's lymphoma.
› Verified 2 days ago
| Entity Name | Emergency Physicians Of Tidewater |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033136841 PECOS PAC ID: 5092618462 Enrollment ID: O20040202000195 |
News Archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of New Jersey denied Teva's motion to overturn an April 23, 2010, jury verdict finding the patent in suit not invalid. The Court also denied Wyeth and Nycomed's request for FDA to reset the date of Teva's final approval to January 2011, based on the fact that Teva has patent defenses remaining at the District Court, including patent misuse.
Codexis, Inc., a developer of industrial enzymes to enable the cost advantaged production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the FDA has approved a new process co-developed by Codexis for the manufacture of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia.
People with certain blood types are more likely to have blood clots or bleeding conditions, kidney stones, or pregnancy-induced hypertension, suggests a study published today in eLife.
One of the most significant ways in which the human brain is unique is the size and structure of the cerebral cortex. But what drives the growth of the human cortex, likely the foundation for our unique intellectual abilities?
Cell Therapeutics, Inc. announced the publication of results posted in the online journal of Cancer of a Phase I-II study that evaluated the safety and efficacy of pixantrone when used in combination with fludarabine, dexamethasone and rituximab replacing mitoxantrone in the standard FND-R regimen with FPD-R among 28 patients with relapsed or refractory indolent non-Hodgkin's lymphoma.
› Verified 2 days ago
| Entity Name | Hyperbaric Physician Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689642027 PECOS PAC ID: 6507806478 Enrollment ID: O20050510000798 |
News Archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of New Jersey denied Teva's motion to overturn an April 23, 2010, jury verdict finding the patent in suit not invalid. The Court also denied Wyeth and Nycomed's request for FDA to reset the date of Teva's final approval to January 2011, based on the fact that Teva has patent defenses remaining at the District Court, including patent misuse.
Codexis, Inc., a developer of industrial enzymes to enable the cost advantaged production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the FDA has approved a new process co-developed by Codexis for the manufacture of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia.
People with certain blood types are more likely to have blood clots or bleeding conditions, kidney stones, or pregnancy-induced hypertension, suggests a study published today in eLife.
One of the most significant ways in which the human brain is unique is the size and structure of the cerebral cortex. But what drives the growth of the human cortex, likely the foundation for our unique intellectual abilities?
Cell Therapeutics, Inc. announced the publication of results posted in the online journal of Cancer of a Phase I-II study that evaluated the safety and efficacy of pixantrone when used in combination with fludarabine, dexamethasone and rituximab replacing mitoxantrone in the standard FND-R regimen with FPD-R among 28 patients with relapsed or refractory indolent non-Hodgkin's lymphoma.
› Verified 2 days ago
| Entity Name | Observation Physicians Of Tidewater |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306590450 PECOS PAC ID: 8123401429 Enrollment ID: O20220819000428 |
News Archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of New Jersey denied Teva's motion to overturn an April 23, 2010, jury verdict finding the patent in suit not invalid. The Court also denied Wyeth and Nycomed's request for FDA to reset the date of Teva's final approval to January 2011, based on the fact that Teva has patent defenses remaining at the District Court, including patent misuse.
Codexis, Inc., a developer of industrial enzymes to enable the cost advantaged production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the FDA has approved a new process co-developed by Codexis for the manufacture of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia.
People with certain blood types are more likely to have blood clots or bleeding conditions, kidney stones, or pregnancy-induced hypertension, suggests a study published today in eLife.
One of the most significant ways in which the human brain is unique is the size and structure of the cerebral cortex. But what drives the growth of the human cortex, likely the foundation for our unique intellectual abilities?
Cell Therapeutics, Inc. announced the publication of results posted in the online journal of Cancer of a Phase I-II study that evaluated the safety and efficacy of pixantrone when used in combination with fludarabine, dexamethasone and rituximab replacing mitoxantrone in the standard FND-R regimen with FPD-R among 28 patients with relapsed or refractory indolent non-Hodgkin's lymphoma.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul S Holota, MD Po Box 7549, Portsmouth, VA 23707-0549 Ph: (757) 686-3508 | Paul S Holota, MD 4092 Foxwood Dr, Suite 101, Virginia Beach, VA 23462-5225 Ph: (757) 467-4200 |
News Archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of New Jersey denied Teva's motion to overturn an April 23, 2010, jury verdict finding the patent in suit not invalid. The Court also denied Wyeth and Nycomed's request for FDA to reset the date of Teva's final approval to January 2011, based on the fact that Teva has patent defenses remaining at the District Court, including patent misuse.
Codexis, Inc., a developer of industrial enzymes to enable the cost advantaged production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the FDA has approved a new process co-developed by Codexis for the manufacture of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia.
People with certain blood types are more likely to have blood clots or bleeding conditions, kidney stones, or pregnancy-induced hypertension, suggests a study published today in eLife.
One of the most significant ways in which the human brain is unique is the size and structure of the cerebral cortex. But what drives the growth of the human cortex, likely the foundation for our unique intellectual abilities?
Cell Therapeutics, Inc. announced the publication of results posted in the online journal of Cancer of a Phase I-II study that evaluated the safety and efficacy of pixantrone when used in combination with fludarabine, dexamethasone and rituximab replacing mitoxantrone in the standard FND-R regimen with FPD-R among 28 patients with relapsed or refractory indolent non-Hodgkin's lymphoma.
› Verified 2 days ago
Ioliene Boenau, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3914 W Stratford Rd, Virginia Beach, VA 23455 Phone: 757-460-5924 | |
Moss H Mendelson, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4092 Foxwood Dr, Suite 101, Virginia Beach, VA 23462 Phone: 757-467-4200 | |
Anthony C Cetrone, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 6632 Indian River Rd, Virginia Beach, VA 23464 Phone: 757-424-4300 Fax: 757-523-0632 | |
Dr. Natalie Sobota Feldman, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4092 Foxwood Dr, Ste 101, Virginia Beach, VA 23462 Phone: 757-686-3508 Fax: 757-686-0541 | |
Christopher L Gibert, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4092 Foxwood Dr, Suite 101, Virginia Beach, VA 23462 Phone: 757-467-4200 | |
Dr. Andy Cameron Bunch, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4092 Foxwood Dr Ste 101, Virginia Beach, VA 23462 Phone: 757-467-4200 | |
Beverly Nyokabi, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4445 Corporation Ln Ste 264, Virginia Beach, VA 23462 Phone: 540-776-4028 |